RxDoctor Payments Data

Susan Littman, MD

Internal Medicine · Ambler, PANPI 1437349321

Payments from drug & device makers

$609in general payments, 2019–2025

Across 32 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$88
  • Novo Nordisk$86
  • AbbVie$70
  • Lilly USA, LLC$66
  • Sunovion Pharmaceuticals Inc.$54
  • Astellas Pharma US Inc$38
  • plus $208 from 10 others

What the payments were for

  • Food & beverage$609100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$609 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$113,409
Medicare patients
126
Services billed
881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine49$176,498
EliquisApixaban111$66,009
MyrbetriqMirabegron64$30,067
JanuviaSitagliptin Phosphate25$22,234
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,428
Breo ElliptaFluticasone/Vilanterol35$14,712
ZenpepLipase/Protease/Amylase17$14,146
XareltoRivaroxaban23$13,178
GemtesaVibegron17$8,264
Atorvastatin Calcium437$6,513
Memantine Hcl ErMemantine Hcl56$6,287
RytaryCarbidopa/Levodopa13$4,283
Potassium Chloride227$4,239
Mirtazapine185$3,960
RocklatanNetarsudil Mesylat/Latanoprost11$3,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$66,009111 claims
GSKTrelegy Ellipta, Breo Ellipta$16$30,13959 claims
Astellas Pharma US IncMyrbetriq$38$30,06764 claims
Johnson & JohnsonXarelto$17$13,17823 claims
Lilly USA, LLCOlanzapine$66$1,62790 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Ambler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →